Rybelsus (Semaglutide Pill): Doses, SNAC, and 2026 Status

What Is Rybelsus? The Direct Answer

Rybelsus is semaglutide in tablet form. Same molecule as the Ozempic pen, same drug class, delivered by mouth instead of by needle. The FDA approved it in September 2019, and that approval was a first: no GLP-1 receptor agonist had ever been made to survive the trip through a stomach before.

What it is approved to do is narrower than most people assume. Rybelsus is indicated for improving blood sugar in adults with type 2 diabetes, alongside diet and exercise. In October 2025 the label expanded to include reducing the risk of major cardiovascular events, meaning cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes who are at high risk for these events. Weight loss is not on the label at any dose.

Its status in 2026 deserves a precise answer rather than a tidy one. Rybelsus is still sold and still marketed under its own name today, and people with existing prescriptions are still filling them. At the same time, Novo Nordisk is transitioning new US prescriptions to a reformulated, renamed successor: the Ozempic pill, in 1.5, 4, and 9 mg strengths, which launched in US pharmacies on May 4, 2026. Novo Nordisk's guidance to anyone currently on Rybelsus is to continue their current medication as directed and speak with their prescriber about transitioning to the Ozempic pill. Outside the US, Rybelsus continues under its own name. So the honest framing is neither "Rybelsus is gone" nor "Rybelsus is the current oral semaglutide," but a product mid-handover.

One more distinction, because searches for the semaglutide pill collapse two products into one. The oral semaglutide approved for weight management is a separate product, the Wegovy pill at 25 mg daily. Rybelsus sits on the diabetes side of that wall.

Rybelsus Dosing: The 3 mg to 7 mg to 14 mg Ladder

Rybelsus is titrated, meaning the dose climbs in fixed steps rather than starting where it will finish. Every step holds for 30 days before the next increase.

The Rybelsus titration ladder holds each step for 30 days before the next increase.

The 3 mg tablet is worth understanding properly, because a flat blood sugar result at the end of that first month reads like failure and usually is not. The label states plainly that this dose is not effective for glycaemic control. It exists to let the gut adapt before a therapeutic amount arrives, which keeps early nausea manageable. Real glucose lowering starts at 7 mg, and 14 mg is the ceiling for this formulation. Two 7 mg tablets are not a substitute for one 14 mg tablet.

How Rybelsus Works: The SNAC Absorption Breakthrough

Why oral peptides normally fail

Semaglutide is a peptide, a chain of amino acids. The stomach is purpose-built to take chains of amino acids apart, because that is what digestion is, so a swallowed peptide drug gets treated as breakfast. That single problem is why every other GLP-1 arrives as an injection: bypassing the gut was easier than surviving it.

What SNAC does

The workaround is a second ingredient pressed into the same tablet. SNAC, or salcaprozate sodium, is a small-molecule absorption enhancer. As the tablet dissolves it raises the pH in the small pocket of stomach lining right next to it, creating a local zone where semaglutide is shielded from enzymatic breakdown, and it helps the drug cross the gastric epithelium at that spot before it drifts away and dilutes below a useful concentration. Buckley and colleagues described this transcellular stomach absorption route in Science Translational Medicine in 2018, and their work established that efficient absorption of oral semaglutide depends on SNAC being present.

SNAC creates a localised pH-buffered zone at the stomach wall, letting semaglutide cross before it dilutes.

The mechanism works, but it is not efficient. Solis-Herrera and colleagues put oral semaglutide's bioavailability at 0.8%. The Ozempic injection label, for comparison, gives absolute bioavailability for subcutaneous semaglutide as 89%. So around 99% of a swallowed dose never reaches the bloodstream. Two practical consequences follow. First, it explains the milligram gap: a 14 mg tablet and a 1 mg injection are not comparable amounts of delivered drug, and the tablet is not fourteen times stronger. Second, it explains why the administration rules are non-negotiable rather than advisory. When only a fraction of a dose is getting through, anything that dilutes the drug at the stomach wall does measurable damage to the amount absorbed. For the receptor-level biology that follows once semaglutide is in circulation, see how semaglutide works.

How to Take Rybelsus (and Why the Rules Are Strict)

This is the most practically important part of the page, because Rybelsus taken casually is closer to no medication than to a lower dose. Solis-Herrera and colleagues set out the requirement clearly: take oral semaglutide in the fasting state, before the first food, beverage, or other oral medication of the day, with no more than 120 mL (4 oz) of plain water, followed by a post-dose fast of at least 30 minutes.

Each rule maps onto the mechanism from the previous section. Food in the stomach disperses the tablet, so the local pH pocket SNAC needs never forms properly. A large glass of water does the same thing by volume. Other oral medications compete for the same window. The 30-minute wait is the time the absorption process needs before normal digestion resumes.

Two mechanical points follow. The tablet must be swallowed whole, since crushing, splitting, or chewing it destroys the co-formulated delivery system the drug depends on. And a missed dose is skipped rather than doubled up later, because a second tablet on a full stomach absorbs poorly anyway. A prescriber or pharmacist can confirm the right approach where other morning medications are involved.

What the Semaglutide Pill Treats (and What It Doesn't)

The Rybelsus label covers two things. The first is glycaemic control: improving blood sugar in adults with type 2 diabetes as an adjunct to diet and exercise. The second, added in October 2025, is reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them, an expansion supported by the SOUL trial. The wording is worth reading carefully. The label does not require a prior heart attack or stroke, and in SOUL 13% of participants had chronic kidney disease with no cardiovascular disease at all. But "high risk" is not open-ended: everyone in the trial was 50 or older with established cardiovascular disease or chronic kidney disease, so this is not an indication for type 2 diabetes plus risk factors alone. That expansion made oral semaglutide the first tablet-form GLP-1 to carry a cardiovascular indication.

For the wider type 2 diabetes picture, including the SUSTAIN trial programme behind injectable semaglutide and how oral and injectable options are positioned against each other in practice, see semaglutide for type 2 diabetes.

Does Rybelsus Cause Weight Loss? PIONEER Trial Data

Weight change was measured in the trials, so there is a real answer here. In PIONEER 1 (Aroda et al., Diabetes Care, 2019), oral semaglutide monotherapy produced greater HbA1c reduction than placebo across all three doses in adults with type 2 diabetes, and greater weight loss than placebo at the 14 mg dose. The direction is consistent: weight comes down, and more so at the top of the ladder.

PIONEER 6 (Husain et al., New England Journal of Medicine, 2019) was the cardiovascular safety trial that underpinned the original approval. It randomised 3,183 adults with type 2 diabetes at high cardiovascular risk and found oral semaglutide non-inferior to placebo for major adverse cardiovascular events. That is a safety finding rather than a benefit claim, and it is the groundwork the later SOUL trial built the 2025 cardiovascular indication on.

None of that makes Rybelsus a weight-loss medication. Weight reduction here is a measured effect in people being treated for diabetes, at doses chosen for glucose control, in a product never submitted for a weight-management indication. Anyone who specifically wants an oral semaglutide for weight is better served by the product studied and approved for that job.

Rybelsus vs Injectable Semaglutide (the Ozempic Pen)

Same molecule, overlapping but not identical approved uses, different delivery. For most people the choice is about format and rhythm, but the labels are not interchangeable, and the table shows where they part company.

The trade is convenience against discipline. The tablet removes the needle but adds a 30-minute window that has to be protected every day rather than once a week. Some people find that easier than an injection and some find it much harder.

What Is Happening to Rybelsus in 2026

Rybelsus is being reformulated and renamed in the United States. The successor is branded as the Ozempic pill, and the strengths were re-engineered from 3, 7, and 14 mg down to 1.5, 4, and 9 mg. The milligram numbers dropped because absorption improved, not because the drug got weaker. The FDA approved it in February 2026 and it reached US pharmacies on May 4, 2026.

As of today the transition is in progress rather than finished. Rybelsus remains available and marketed under its own name, existing prescriptions are still being filled, and Novo Nordisk is asking anyone already on it to continue their current medication as directed and speak with their prescriber about transitioning to the Ozempic pill. The rename is also US-specific. In many other markets Rybelsus continues under the Rybelsus name with the 3, 7, and 14 mg strengths intact.

If you are on Rybelsus now, the practical implication is a refill conversation about a different box with a different number on it, and administration rules that do not change. The full rename story is in is there an Ozempic pill.

Rybelsus Side Effects, Cost, and Access

The side effect profile is the GLP-1 class profile. The label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation as the most common reactions, usually mild to moderate, generally dose-dependent, and most noticeable in the weeks after a dose increase. That pattern is exactly why the 30-day hold at each step exists. Persistent or severe symptoms are a reason to call your prescriber rather than to push through.

The full picture, including the less common effects, is covered in the semaglutide side effects guide.

On access: Rybelsus is prescription-only. There is no legitimate over-the-counter or compounded version, because the tablet is a precision co-formulation with SNAC rather than a peptide that can be repackaged. Pricing moves quickly here, and faster during a brand transition, so current list prices, savings-card routes, and insurance coverage live in the semaglutide cost guide.